NO803951L - Fremgangsmaate for fraksjonering av protein - Google Patents
Fremgangsmaate for fraksjonering av proteinInfo
- Publication number
- NO803951L NO803951L NO803951A NO803951A NO803951L NO 803951 L NO803951 L NO 803951L NO 803951 A NO803951 A NO 803951A NO 803951 A NO803951 A NO 803951A NO 803951 L NO803951 L NO 803951L
- Authority
- NO
- Norway
- Prior art keywords
- protein
- membrane
- solution
- temperature
- plasma
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 124
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 124
- 238000000034 method Methods 0.000 title claims abstract description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 213
- 239000012528 membrane Substances 0.000 claims abstract description 55
- 239000012510 hollow fiber Substances 0.000 claims abstract description 52
- 239000000243 solution Substances 0.000 claims abstract description 32
- 239000002244 precipitate Substances 0.000 claims abstract description 26
- 239000012460 protein solution Substances 0.000 claims abstract description 22
- 238000005194 fractionation Methods 0.000 claims abstract description 18
- 238000005119 centrifugation Methods 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 238000011026 diafiltration Methods 0.000 claims abstract description 7
- 239000010419 fine particle Substances 0.000 claims abstract description 4
- 210000002381 plasma Anatomy 0.000 claims description 114
- 102000009027 Albumins Human genes 0.000 claims description 38
- 108010088751 Albumins Proteins 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 28
- 238000000926 separation method Methods 0.000 claims description 16
- 239000000835 fiber Substances 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 108010017384 Blood Proteins Proteins 0.000 claims description 9
- 102000004506 Blood Proteins Human genes 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 238000005086 pumping Methods 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 239000012466 permeate Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 239000006096 absorbing agent Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 230000036425 denaturation Effects 0.000 abstract description 17
- 238000004925 denaturation Methods 0.000 abstract description 17
- 230000008569 process Effects 0.000 abstract description 14
- 230000001376 precipitating effect Effects 0.000 abstract description 7
- 238000001816 cooling Methods 0.000 description 19
- 238000002156 mixing Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 239000007974 sodium acetate buffer Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005187 foaming Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 108010074605 gamma-Globulins Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010058936 Cohn fraction V Proteins 0.000 description 2
- 238000000665 Cohn process Methods 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000013494 PH determination Methods 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WDKOADZMAHHGKP-UHFFFAOYSA-N 3-ethenylpenta-2,4-dienenitrile Chemical compound C(=C)C(=CC#N)C=C WDKOADZMAHHGKP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000011001 backwashing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/10—Temperature control
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Water Supply & Treatment (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3603179A | 1979-05-04 | 1979-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO803951L true NO803951L (no) | 1980-12-29 |
Family
ID=21886215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO803951A NO803951L (no) | 1979-05-04 | 1980-12-29 | Fremgangsmaate for fraksjonering av protein |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0028246A4 (de) |
| JP (1) | JPS56500442A (de) |
| AR (1) | AR224765A1 (de) |
| BE (1) | BE883099A (de) |
| CA (1) | CA1161368A (de) |
| DK (1) | DK537380A (de) |
| ES (1) | ES8107244A1 (de) |
| FI (1) | FI801439A (de) |
| FR (1) | FR2455608A1 (de) |
| GR (1) | GR68187B (de) |
| IL (1) | IL59975A (de) |
| IT (1) | IT1131137B (de) |
| NO (1) | NO803951L (de) |
| NZ (1) | NZ193605A (de) |
| PT (1) | PT71179B (de) |
| WO (1) | WO1980002380A1 (de) |
| ZA (1) | ZA802667B (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100004496A1 (it) * | 2021-02-25 | 2022-08-25 | Univ Della Calabria | Recupero di farmaci biologici o loro frammenti da soluzioni impure mediante cristallizzazione o precipitazione con membrane |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390074A (en) * | 1942-02-09 | 1945-12-04 | Research Corp | Protein product and process |
| US2469193A (en) * | 1942-02-09 | 1949-05-03 | Research Corp | Protein fractionation |
| US2770616A (en) * | 1951-01-29 | 1956-11-13 | Protein Foundation Inc | Fractionation of proteinaceous materials in blood plasma and liver tissue |
| GB1323681A (en) * | 1969-03-28 | 1973-07-18 | Nat Res Dev | Apparatus for use in the fractionation of solutions of protein aceous materials |
| US3869436A (en) * | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
| US3763135A (en) * | 1971-11-08 | 1973-10-02 | Baxter Laboratories Inc | Gamma globulin production from cohn fraction iii using polyethylene glycol |
| US4142966A (en) * | 1974-04-01 | 1979-03-06 | Monsanto Company | Membrane separation of water from aqueous mixtures |
| DE2444524A1 (de) * | 1974-09-18 | 1976-04-08 | Oeser Henning Dr | Verfahren und vorrichtung zur ausfaellung von human-blutplasma-bestandteilen |
| US3998946A (en) * | 1975-04-23 | 1976-12-21 | The Regents Of The University Of Minnesota | Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same |
| SE393535B (sv) * | 1975-09-11 | 1977-05-16 | Gambro Ab | Anordning for diffusion av emnen mellan tva fluider via semipermeabla membran |
| US4218312A (en) * | 1975-12-01 | 1980-08-19 | Monsanto Company | Membrane separation of organics from aqueous solutions |
| FR2380362A2 (fr) * | 1976-02-13 | 1978-09-08 | Baxter Travenol Lab | Faisceau de filaments creux, et procede et appareil d'enroulement de filaments creux |
| NL7711855A (nl) * | 1977-02-11 | 1978-08-15 | Baxter Travenol Lab | Werkwijze en inrichting voor het vervaardigen van filamentbundels en dergelijke bundels be- vattende dialysators. |
| DE2725757A1 (de) * | 1977-06-07 | 1978-12-21 | Fresenius Chem Pharm Ind | Vorrichtung zur fortlaufenden analyse niedermolekularer bestandteile in stroemenden fluessigkeiten |
| US4136094A (en) * | 1977-08-31 | 1979-01-23 | The Regents Of The University Of Minnesota | Preparation of intravenous human and animal gamma globulins and isolation of albumin |
-
1980
- 1980-04-29 GR GR61811A patent/GR68187B/el unknown
- 1980-04-30 FR FR8009775A patent/FR2455608A1/fr not_active Withdrawn
- 1980-05-01 WO PCT/US1980/000481 patent/WO1980002380A1/en not_active Application Discontinuation
- 1980-05-01 CA CA000351044A patent/CA1161368A/en not_active Expired
- 1980-05-01 IL IL59975A patent/IL59975A/xx unknown
- 1980-05-01 JP JP50127480A patent/JPS56500442A/ja active Pending
- 1980-05-02 ES ES491138A patent/ES8107244A1/es not_active Expired
- 1980-05-02 AR AR280887A patent/AR224765A1/es active
- 1980-05-02 ZA ZA00802667A patent/ZA802667B/xx unknown
- 1980-05-02 PT PT71179A patent/PT71179B/pt unknown
- 1980-05-02 BE BE6/47155A patent/BE883099A/fr not_active IP Right Cessation
- 1980-05-02 NZ NZ193605A patent/NZ193605A/xx unknown
- 1980-05-02 IT IT21790/80A patent/IT1131137B/it active
- 1980-05-05 FI FI801439A patent/FI801439A/fi not_active Application Discontinuation
- 1980-11-17 EP EP19800901060 patent/EP0028246A4/de not_active Withdrawn
- 1980-12-17 DK DK537380A patent/DK537380A/da not_active Application Discontinuation
- 1980-12-29 NO NO803951A patent/NO803951L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR224765A1 (es) | 1982-01-15 |
| BE883099A (fr) | 1980-11-03 |
| ZA802667B (en) | 1981-06-24 |
| FR2455608A1 (fr) | 1980-11-28 |
| WO1980002380A1 (en) | 1980-11-13 |
| GR68187B (de) | 1981-11-09 |
| PT71179A (en) | 1980-07-01 |
| IT8021790A0 (it) | 1980-05-02 |
| ES491138A0 (es) | 1981-05-16 |
| FI801439A (fi) | 1980-11-05 |
| ES8107244A1 (es) | 1981-05-16 |
| IT1131137B (it) | 1986-06-18 |
| CA1161368A (en) | 1984-01-31 |
| EP0028246A1 (de) | 1981-05-13 |
| DK537380A (da) | 1980-12-17 |
| IL59975A (en) | 1983-07-31 |
| PT71179B (en) | 1982-06-20 |
| IL59975A0 (en) | 1980-07-31 |
| NZ193605A (en) | 1983-05-10 |
| EP0028246A4 (de) | 1982-03-29 |
| JPS56500442A (de) | 1981-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Herriott | Isolation, crystallization, and properties of swine pepsinogen | |
| US4188318A (en) | Simplified method for preparation of high yield, high purity Factor VIII concentrate | |
| US2390074A (en) | Protein product and process | |
| US6139878A (en) | Method for preparing a diafiltered stabilized blood product | |
| NO320952B1 (no) | Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl | |
| CA2621025A1 (en) | An ultra-high yield intravenous immune globulin preparation | |
| US2469193A (en) | Protein fractionation | |
| US5259971A (en) | Method of preparing fibrinogen | |
| AU2006287833A1 (en) | An ultra-high yield intravenous immune globulin preparation | |
| EP0511277B1 (de) | Magermilchbehandlungsverfahren | |
| CN104402993A (zh) | 一种制备静注人免疫球蛋白的方法 | |
| CN104328101A (zh) | 一种凝血酶的制备方法 | |
| WO1993017776A9 (en) | Method of preparing fibrinogen | |
| US4624780A (en) | Fractionation of blood plasma | |
| NO803951L (no) | Fremgangsmaate for fraksjonering av protein | |
| PL139882B1 (en) | Method of obtaining from calf blood active substances which promote tissue respiration | |
| Charm et al. | [37] Scale-Up of protein isolation | |
| CN103450356A (zh) | 一种高纯度胸腺肽的制备方法 | |
| CH652932A5 (fr) | Procede pour la preparation d'un concentrat purifie de facteur antihemophile. | |
| Snir et al. | pH and cations influence permeability of marsh grapefruit pectinesterase on polysulfone ultrafiltration membrane | |
| US4956290A (en) | Large scale process for the purification of alcohol oxidase | |
| CN112521486A (zh) | 一种乙醇实时控制的低温乙醇分离人血白蛋白的生产方法 | |
| Sprinchan | Optimization of technological regimes for obtaining protein-mineral concentrated products from secondary milk raw materials | |
| RU2324495C1 (ru) | Способ получения препарата фактора свертывания viii крови человека | |
| US4486341A (en) | Fractionation of blood plasma |